相关实验视频
Updated: Jun 26, 2025
08:36
Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3
Published on: April 7, 2023
1.1K
在脊椎关节炎中选择性JAK抑制剂
Konstantinos D Vassilakis1, Konstantina Magiouf1, Stefan Siebert2
1Joint Academic Rheumatology Program, First Department of Propaedeutic and Internal Medicine, National and Kapodistrian University of Athens, Athens, Greece.
Mediterranean journal of rheumatology
|May 17, 2024
概括
雅努斯酶抑制剂 (JAKi) 通过向JAK-STAT通路,为脊椎关节炎提供了一种新的治疗方法. 本综述评估了JAK抑制剂的疗效和安全性,包括选择性选择,用于牛皮关节炎和轴性脊柱关节炎.
科学领域:
- 类风湿病学 类风湿病学
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
背景情况:
- 脊椎关节炎 (SpA) 包括诸如牛皮关节炎 (PsA) 和轴性脊椎关节炎 (AxSpA) 这样的疾病.
- JAK-STAT通路与SPA的病理生理学有关.
- 简氏激酶抑制剂 (JAKi) 是一种针对这种途径的新型治疗类.
研究的目的:
- 审查和评估JAK抑制剂在治疗SpA中的当前疗效.
- 评估JAK抑制剂在SPA患者中的安全性.
- 专注于选择性JAK抑制剂在PsA和AxSpA管理中的作用.
主要方法:
- 对SPA中JAK抑制剂现有研究的文献综述.
- 对临床试验数据关于疗效和安全性的分析.
- 基于它们对JAK家族成员的选择性 (JAK1,JAK2,JAK3,TYK2) 的不同JAK抑制剂的比较.
主要成果:
- JAK 抑制剂在控制 SpA 症状方面显示出潜在的有效性.
- 不同的JAK抑制剂具有不同的选择性,可能会影响结果.
- 对SPA的累积数据与在类风湿性关节炎中更成熟的数据形成鲜明对比.
结论:
- 雅克抑制剂是对SPA的一种有前途的治疗选择.
- 需要进一步的研究,以充分了解选择性JAK抑制剂在PsA和AxSpA中的疗效和安全性.
- 仔细考虑个体患者的个人资料和JAK抑制剂的选择性对于最佳治疗至关重要.
相关概念视频
01:20The JAK-STAT Signaling Pathway
8.8K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
8.8K
01:19Antiasthma Drugs: Leukotriene Modifiers
281
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
281
01:25Dose-Response Relationship: Selectivity and Specificity
6.7K
Drugs exert their therapeutic effects by interacting with receptors, enzymes, or ion channels that are present throughout the human body. The strength and duration of the interaction between a drug and its target receptor are characterized by the selectivity and specificity of the drug. Selectivity refers to a drug's strong preference for its intended target over other targets. For instance, isoprenaline, a non-selective β-adrenergic agonist, interacts with both β1- and...
6.7K
01:25Antihypertensive Drugs: Direct Renin Inhibitors
601
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
601
01:29Spasmolytic Agents: Chemical Classification
879
Spasmolytic agents are drugs used to alleviate muscle spasms and spasticity. They can be categorized into different chemical groups based on their mechanisms of action. Centrally acting spasmolytics primarily affect the spinal cord, while others directly target skeletal muscle cells.
A major class of centrally acting spasmolytics is the α2-agonist, such as tizanidine. These drugs bind to α2-adrenoceptors, inhibiting the release of the excitatory neurotransmitter glutamate. They also...
A major class of centrally acting spasmolytics is the α2-agonist, such as tizanidine. These drugs bind to α2-adrenoceptors, inhibiting the release of the excitatory neurotransmitter glutamate. They also...
879
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
131
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
131